Page last updated: 2024-09-04

oxypeucadanin and Lung Injury, Acute

oxypeucadanin has been researched along with Lung Injury, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Du, L; Jia, Y; Kan, X; Li, C; Meng, G; Wang, Q; Zhang, J; Zhang, X	1

Other Studies

1 other study(ies) available for oxypeucadanin and Lung Injury, Acute

Article	Year
Oxypeucedanin relieves LPS-induced acute lung injury by inhibiting the inflammation and maintaining the integrity of the lung air-blood barrier. Aging, 2022, Aug-18, Volume: 14, Issue:16 Topics: Acute Lung Injury; Anti-Inflammatory Agents; Blood-Air Barrier; Furocoumarins; Humans; Inflammation; Lipopolysaccharides; Lung; NF-kappa B; Peroxidase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt	2022

Article

Year

Oxypeucedanin relieves LPS-induced acute lung injury by inhibiting the inflammation and maintaining the integrity of the lung air-blood barrier.

Aging, 2022, Aug-18, Volume: 14, Issue:16

Topics: Acute Lung Injury; Anti-Inflammatory Agents; Blood-Air Barrier; Furocoumarins; Humans; Inflammation; Lipopolysaccharides; Lung; NF-kappa B; Peroxidase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt

2022